Plasmids are an important starting material for the manufacturing of mRNA- and cell-based drugsThe new plasmid manufacturing facility aims to increase BioNTech’s autonomy and flexibility in manufacturing an important starting material for its oncology and COVID-19 vaccine pipeline The investment of approximately €40 million is part of a long-term development plan for BioNTech’s manufacturing site in Marburg German Chancellor Olaf Scholz is visiting the facility together with BioNTech co-founders
Today is shaping up negative for BioNTech SE ( NASDAQ:BNTX ) shareholders, with the analysts delivering a substantial...
Pfizer/BioNTech, Moderna and Novavax are included in this Analyst Blog.